(Q28286064)

English

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

scientific article

In more languages

Statements

scholarly article

0 references

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (English)

0 references

phase III clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Georg Maschmeyer

3

object named as

Georg Maschmeyer

0 references

author name string

Mathias J Rummel

1

0 references

Norbert Niederle

2

0 references

G Andre Banat

4

0 references

Ulrich von Grünhagen

5

0 references

Christoph Losem

6

0 references

Dorothea Kofahl-Krause

7

0 references

Gerhard Heil

8

0 references

Manfred Welslau

9

0 references

Christina Balser

10

0 references

Ulrich Kaiser

11

0 references

Eckhart Weidmann

12

0 references

Heinz Dürk

13

0 references

Harald Ballo

14

0 references

Martina Stauch

15

0 references

Fritz Roller

16

0 references

Juergen Barth

17

0 references

Dieter Hoelzer

18

0 references

Axel Hinke

19

0 references

Wolfram Brugger

20

0 references

language of work or name

0 references

publication date

6 April 2013

0 references

0 references

381

0 references

9873

0 references

1203-10

0 references

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma, survival, and rituximab: is it time to declare victory?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma in the United States: first report of the national LymphoCare study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine: rebirth of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Current treatment standards and future strategies in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961763-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)61763-2

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28286064&oldid=2092823619"